Zolmitriptan: a review of its use in migraine (Q33726243)

28 July 2017

1 reference

title

Zolmitriptan: a review of its use in migraine (English)

1 reference

28 July 2017

1 reference

C M Spencer

1

1 reference

28 July 2017

N S Gunasekara

series ordinal

2

1 reference

28 July 2017

C Hills

series ordinal

3

1 reference

28 July 2017

publication date

1 August 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

58

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

347-374

1 reference

The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90)

28 July 2017

cites work

1 reference

12 December 2020

The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers.

1 reference

12 December 2020

Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura?

1 reference

12 December 2020

Clinical presentation and treatment of migraine

1 reference

12 December 2020

Side effects of ergotamine

1 reference

12 December 2020

Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers

1 reference

12 December 2020

The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.

1 reference

12 December 2020

The clinical pharmacokinetics of zolmitriptan.

1 reference

12 December 2020

311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists

1 reference

12 December 2020

Migraine in the United States: a review of epidemiology and health care use.

1 reference

12 December 2020

The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers

1 reference

12 December 2020

The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group

1 reference

12 December 2020

No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.

1 reference

12 December 2020

Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.

1 reference

12 December 2020

Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study

1 reference

12 December 2020

Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90)

1 reference

12 December 2020

Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

1 reference

12 December 2020

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

1 reference

12 December 2020

Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).

1 reference

12 December 2020

Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers

1 reference

12 December 2020

Migraine Symptoms: Results of a Survey of Self‐Reported Migraineurs

1 reference

12 December 2020

Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.

1 reference

12 December 2020

Effects of Zolmitriptan (ZomigTM) on Central Serotonergic Neurotransmission as Assessed by Active Oddball Auditory Event-Related Potentials in Volunteers without Migraine

1 reference

12 December 2020

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

1 reference

12 December 2020

Current concepts of migraine pathogenesis.

1 reference

12 December 2020

Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

1 reference

12 December 2020

Diagnosis and management of migraine

1 reference

12 December 2020

Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine

1 reference

12 December 2020

311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.

1 reference

12 December 2020

Sumatriptan. An updated review of its use in migraine

1 reference

12 December 2020

A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine

1 reference

12 December 2020

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group

1 reference

12 December 2020

Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy

1 reference

12 December 2020

The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide

1 reference

12 December 2020

The burden of migraine. A review of cost to society

1 reference

12 December 2020

Coronary side-effect potential of current and prospective antimigraine drugs

1 reference

12 December 2020

Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.

1 reference

12 December 2020

Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).

1 reference

12 December 2020

311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study

1 reference

12 December 2020

Headache after frequent use of serotonin agonists zolmitriptan and naratriptan

1 reference

12 December 2020

Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine

1 reference

12 December 2020

1 reference

12 December 2020

The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers

1 reference

12 December 2020

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group

1 reference

12 December 2020

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

1 reference

12 December 2020

Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society

1 reference

12 December 2020

Burden of migraine: societal costs and therapeutic opportunities

1 reference

12 December 2020

Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers

1 reference

12 December 2020

Lack of an effect of zolmitriptan (Zomig, 311C90) on psychometric task performance: results of a placebo-controlled study in healthy volunteers

1 reference

12 December 2020

The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers

1 reference

12 December 2020

Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine

1 reference

12 December 2020

Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache

1 reference

12 December 2020

The mode of action of sumatriptan is vascular? A debate

1 reference

12 December 2020

10.2165/00003495-199958020-00016

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1000668350

0 references

1 reference